NMN is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Solid NMN is generally handled as a moisture-sensitive and light-sensitive material. Suppliers commonly recommend storage at minus 20 degrees Celsius in a sealed, desiccated container, protected from light. Aqueous solutions are less stable than the solid and may degrade faster at elevated temperatures or extreme pH values. Because NMN contains a phosphate ester and a glycosidic bond, hydrolysis and other degradation pathways are plausible under unfavorable conditions. Stability data from independent laboratories remain limited, so handling recommendations often reflect supplier practice rather than published consensus.
Analytical measurement of NMN typically uses high-performance liquid chromatography with ultraviolet detection, often at a wavelength near 260 nanometers. Liquid chromatography coupled with tandem mass spectrometry provides greater sensitivity and specificity, especially for biological samples. Nuclear magnetic resonance spectroscopy can confirm structure and detect certain impurities. Purity values reported by suppliers depend on the analytical method, calibration standards, and whether related compounds such as nicotinamide or NAD+ are included in the calculation. Independent verification is useful because supplement labels may not fully describe the tested material.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide derivative of nicotinamide |
| Molecular formula | C11H15N2O8P | Free acid form; salts may differ |
| Molar mass | 334.22 g/mol | Approximate value for free acid |
| CAS Registry Number | 1094-61-7 | Common beta isomer |
| Solubility | Water-soluble | Polar molecule; solubility varies with pH and form |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
=== Early studies === The first direct examination of the shroud by a scientific team was undertaken in 1969–1973 in order to advise on preservation of the shroud and determine specific testing methods. This led to the appointment of an 11-member Turin Commission to advise on the preservation of the relic and on specific testing. Five of the commission members were scientists, and preliminary studies of samples of the fabric were conducted in 1973. In 1976 the physicist John P. Jackson, the thermodynamicist Eric Jumper and the photographer William Mottern used image analysis technologies developed in aerospace science for analyzing the images of the Shroud. In 1977 these three scientists and over thirty other experts in various fields formed the Shroud of Turin Research Project. In 1978 this group, often called STURP, was given direct access to the Shroud. Joe Nickell of the Committee for Skeptical Inquiry has pointed out that "STURP's leaders served on the executive council of the Holy Shroud Guild, which is devoted to the "cause" of the reputed relic", a group whose motivation it was to campaign for the legitimacy of the Turin shroud. Paleontologist Steven Schafersman has described STURP as "an organization totally composed of believers in the authenticity of the Shroud", with the exception of a single agnostic being Walter McCrone. Also in 1978, independently from the STURP research, Giovanni Tamburelli obtained at CSELT a 3D-elaboration from the Shroud with higher resolution than Jumper and Mottern.
== Taxonomy == Carl Linnaeus described the species in 1771, the specific epithet biloba derived from the Latin bis, "twice" and loba, "lobed", referring to the shape of the leaves. Two names for the species recognise the botanist Richard Salisbury, a placement by Nelson as Pterophyllus salisburiensis and the earlier Salisburia adiantifolia proposed by James Edward Smith. The epithet of the latter may have been intended to denote a characteristic resembling Adiantum, the genus of maidenhair ferns. The generic name Ginkgo can be traced to recordings done by Engelbert Kaempfer, the first Westerner to investigate the species in 1690 in Nagasaki, for the Amoenitates Exoticae (1712): it is regarded as a mistranscription of Japanese 銀杏 ginkyō ([ɡiŋkʲoː]). Taking his spelling of other Japanese words containing the syllable [kʲoː] (present romanization: kyō) into account, an expected transcription would have been "ginkio" or "ginkjo". Thus, his curious "–kgo" spelling has long been considered to be an error Kaempfer made in his notes, but Nagata et al. showed that it was the spelling of his interpreter, Genemon Imamura, who spoke the local Nagasaki dialect. Linnaeus adopted the ginkgo spelling based on Kaempfer's compilation of Japanese flora in Amoenitates while writing Mantissa plantarum II (Amoenitates Exoticae, p. 811) thus becoming the tree's generic name. Kaempfer's drawing can be found in Hori's article.
== Prevention == In the past, the prophylactic use of dantrolene was recommended for MH-susceptible patients undergoing general anesthesia. However, multiple retrospective studies have demonstrated the safety of trigger-free general anesthesia in these patients in the absence of prophylactic dantrolene administration. The largest of these studies looked at the charts of 2214 patients who underwent general or regional anesthesia for an elective muscle biopsy. About half (1082) of the patients were muscle biopsy positive for MH. Only five of these patients exhibited signs consistent with MH, four of which were treated successfully with parenteral dantrolene, and the remaining one recovered with only symptomatic therapy. After weighing its questionable benefits against its possible adverse effects (including nausea, vomiting, muscle weakness and prolonged duration of action of nondepolarizing neuromuscular blocking agents), experts no longer recommend the use of prophylactic dantrolene prior to trigger-free general anesthesia in MH-susceptible patients.
Sources: en.wikipedia.org
=== Awareness === Awareness of BPD has been growing, with the U.S. House of Representatives declaring May as Borderline Personality Disorder Awareness Month in 2008. Public figures like South Korean singer-songwriter Lee Sun-mi have opened up about their personal experiences with the disorder, bringing further attention to its impact on individuals' lives.
In 1881, Italian physicist Luigi Palmieri detected helium on Earth for the first time through its D3 spectral line, when he analyzed a material that had been sublimated during a recent eruption of Mount Vesuvius.
=== Blood nerve barrier === The peripheral blood nerve barrier is analogous to the blood brain barrier. Like the blood brain barrier, the blood nerve barrier creates a stable, privileged environment where certain substances cannot pass through due to tight junctions. The blood nerve barrier is made up of inner cells of the perineurium and the endothelial cells of the endoneurial microvessels.
Sources: en.wikipedia.org
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.
NMN is converted to NAD+ by NMNAT enzymes. NAD+ is a coenzyme in redox reactions and a substrate for signaling enzymes. This relationship makes NMN a focus of NAD+ research.
No, NMN and nicotinamide riboside are distinct compounds. Nicotinamide riboside can be phosphorylated to form NMN inside cells. Both are studied as NAD+ precursors.
Solid NMN is commonly stored frozen at about minus 20 degrees Celsius, sealed against moisture, and protected from light. Solutions are typically prepared fresh because they can degrade more quickly. Specific storage conditions can vary by supplier and intended use.